Tha Acton Lab is awarded a CRUK-UCL Centre Development Fund

Harnessing our immune system could lead to a future where cancer is curable and non-recurring. Many research approaches have focused towards this aim. The Acton Lab has described mechanisms controlling the physical expansion of lymph nodes, and therefore the scale of adaptive immune responses. They have obtained funds from Cancer Research UK, via the CRUK-UCL Centre, to begin manipulating this signalling mechanism as a novel adjuvant therapy to boost anti-tumour immunity. This project will be carried out in collaboration with Dr Chris Tape, a Career Development Fellow at the UCL Cancer Institute. His group have established protocols for CyTOF analysis (a novel method combining mass spectrometry and flowcytometry) of colorectal cancer organoids. The two laboratories will collaborate to adapt the protocols to lymph node tissues. The Acton Lab propose to use CyTOF to undertake detailed tracking of the developing adaptive immune response. 

For more information about the CRUK-UCL Centre Development Fund, click here.